[Gatsky]

Not sure I agree. Take a look at recently developed antimicrobials. It’s not like there haven’t been any new ones. The problem is this: they are very expensive compared to older antimicrobials (so don’t get used at all except in wealthy healthcare systems) and they are tightly held in reserve for only the most resistant cases (so very small market). The latter point is particularly insurmountable, since widespread use will make the new antimicrobial less useful. It isn’t really worth it for a drug maker. The article talks about this, indicating that public-private partnerships are the way forward.

[Fomite]

They also tend to not be new families of antimicrobials with novel mechanisms of action, which is what's needed for more significant gains against resistance.